دورية أكاديمية

Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland.

التفاصيل البيبلوغرافية
العنوان: Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland.
المؤلفون: Mamas, Mamas A., Sperrin, Matthew, Watson, Margaret C., Coutts, Alasdair, Wilde, Katie, Burton, Christopher, Kadam, Umesh T., Chun Shing Kwok, Clark, Allan B., Murchie, Peter, Buchan, Iain, Hannaford, Philip C., Myint, Phyo K.
المصدر: European Journal of Heart Failure. Supplements; Sep2017, Vol. 19 Issue 9, p1095-1104, 10p
مصطلحات موضوعية: CANCER patients, COLON tumors, CONFIDENCE intervals, HEART failure, LONGITUDINAL method, LUNG tumors, OVARIAN tumors, PRIMARY health care, PROSTATE tumors, RECTUM tumors, SEX distribution, SURVIVAL analysis (Biometry), TUMORS, PROPORTIONAL hazards models
مصطلحات جغرافية: SCOTLAND
مستخلص: Aims This study was designed to evaluate whether survival rates in patients with heart failure (HF) are better than those in patients with diagnoses of the four most common cancers in men and women, respectively, in a contemporary primary care cohort in the community in Scotland. Methods and results Data were obtained from the Primary Care Clinical Informatics Unit from a database of 1.75 million people registered with 393 general practices in Scotland. Sex-specific survival modelling was undertaken using Cox proportional hazards models, adjusted for potential confounders. A total of 56 658 subjects were eligible for inclusion in the study. These represented a total of 147 938 person-years of follow-up (median follow-up: 2.04 years). In men, HF (reference group; 5-year survival: 55.8%) had worse mortality outcomes than prostate cancer [hazard ratio (HR) 0.61, 95% confidence interval (CI) 0.57-0.65; 5-year survival: 68.3%], and bladder cancer (HR 0.88, 95% CI 0.81-0.96; 5-year survival: 57.3%), but better outcomes than lung cancer (HR 3.86, 95% CI 3.65-4.07; 5-year survival: 8.4%) and colorectal cancer (HR 1.23, 95% CI 1.16-1.31; 5-year survival: 48.9%). In women, HF (reference group; 5-year survival: 49.5%) had worse mortality outcomes than breast cancer (HR 0.55, 95% CI 0.51-0.59; 5-year survival 77.7%), but better outcomes than colorectal cancer (HR 1.21, 95% CI 1.13-1.29; 5-year survival 51.5%), lung cancer (HR 3.82, 95% CI 3.60-4.05; 5-year survival 10.4%), and ovarian cancer (HR 1.98, 95% CI 1.80-2.17; 5-year survival 38.2%). Conclusions Despite advances in management, HF remains as 'malignant' as some of the common cancers in both men and women. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Heart Failure. Supplements is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index